Impact of sex on uric acid levels and its relationship with the extent of coronary artery disease: A single-centre study

Atherosclerosis

Volumn 241, Issue 1, 2014, Pages 241-248

  Barbieri, Lucia ^a   Verdoia, Monica ^a   Schaffer, Alon ^a   Marino, Paolo ^a   Suryapranata, Harry ^b   De Luca, Giuseppe ^a  

^a UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Coronary artery disease; Sex; Uric acid

Indexed keywords

URIC ACID; BIOLOGICAL MARKER;

AGED; ANGIOCARDIOGRAPHY; ARTICLE; CORONARY ARTERY DISEASE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; SEX DIFFERENCE; URIC ACID BLOOD LEVEL; BLOOD; CHI SQUARE DISTRIBUTION; COMPARATIVE STUDY; CORONARY ANGIOGRAPHY; CORONARY STENOSIS; CROSS-SECTIONAL STUDY; HEALTH DISPARITY; HYPERURICEMIA; ITALY; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; PREDICTIVE VALUE; RADIOGRAPHY; SEVERITY OF ILLNESS INDEX; UPREGULATION; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BIOMARKERS; CHI-SQUARE DISTRIBUTION; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; CORONARY STENOSIS; CROSS-SECTIONAL STUDIES; FEMALE; HEALTH STATUS DISPARITIES; HUMANS; HYPERURICEMIA; ITALY; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; PREDICTIVE VALUE OF TESTS; PREVALENCE; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SEX FACTORS; UP-REGULATION; URIC ACID;

EID: 84955352442     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2015.03.030     Document Type: Article

References (37)

1. Rosamond W., Flegal K., Friday G., et al. Heart disease and stroke statistics-2007 update: a report from the American Heart Association statistics committee and stroke statistics subcommittee. Circulation 2007, 115:e69-171.
2. Allender S., Scarborough P., Peto V., et al. European cardiovascular disease statistics edition (online). Available from: URL:http://www.enheart.org/files/statistics%202008%20web-161229A.pdf .
3. De Luca G., Bellandi F., Huber K., et al. Early glycoprotein IIb-IIIa inhibitors in primary angioplasty-abciximab long-term results (EGYPT-ALT) cooperation: individual patient's data meta-analysis. J. Thromb. Haemost. 2011, 9:2361-2370.
4. Navarese E.P., De Luca G., Castriota F., et al. Low-molecular-weight heparins vs. unfractionated heparin in the setting of percutaneous coronary intervention for ST-elevation myocardial infarction: a meta-analysis. J. Thromb. Haemost. 1902-15, 2011:9.
5. Navarese E.P., Kubica J., Castriota F., et al. Safety and efficacy of biodegradable vs. durable polymer drug-eluting stents: evidence from a meta-analysis of randomised trials. EuroIntervention 2011, 7:985-994.
6. Natali A., Boldrini B., Baldi S., et al. Impact of mild to moderate reductions of glomerular filtration rate on coronary artery disease severity. Nutr. Metab. Cardiovasc Dis. 2013 Dec 24, [Epub ahead of print].
7. De Luca G., Gibson C.M., Bellandi F., et al. Diabetes mellitus is associated with distal embolization, impaired myocardial perfusion, and higher mortality in patients with ST-segment elevation myocardial infarction treated with primary angioplasty and glycoprotein IIb-IIIa inhibitors. Atherosclerosis 2009, 207:181-185.
8. Tomita M., Mizuno S., Yamanaka H., et al. Does hyperuricemia affect mortality? A prospective cohort study of Japanese male workers. J. Epidemiol. 2000, 10:403-409.
9. Reunanen A., Takkunen H., Knekt P., et al. Hyperuricemia as a risk factor for cardiovascular mortality. Acta Med. Scand. Suppl. 1982, 668:49-59.
10. Levine W., Dyer A.R., Shekelle R.B., et al. Serum uric acid and 11.5-year mortality of middle-aged women: findings of the Chicago Heart Association Detection Project in Industry. J. Clin. Epidemiol. 1989, 42(3):257-267.
11. Lazzeri C., Valente S., Chiostri M., et al. Uric acid in the acute phase of ST elevation myocardial infarction submitted to primary PCI: its prognostic role and relation with inflammatory markers: a single center experience. Int. J. Cardiol. 2010, 138:206-209.
12. De Luca G., Secco G.G., Santagostino M., et al. Uric acid does not affect the prevalence and extent of coronary artery disease. Results from a prospective study. Nutr. Metab. Cardiovasc Dis. 2012, 22:426-433.
13. Holme I., Aastveit A.H., Hammar N., et al. Uric acid and risk of myocardial infarction, stroke and congestive heart failure in 417734 men and women in the Apolipoprotein Mortality RISk study (AMORIS). J. Intern Med. 2009, 266:558-570.
14. Strasak A.M., Kelleher C.C., Brant L.J., et al. Serum uric acid is an independent predictor for all major forms of cardiovascular death in 28613 elderly women: a prospective 21-year follow up study. Int. J. Cardiol. 2008, 125:232-239.
15. Tuttle K.R., Short R.A., Johnson R.J. Sex differences in uric acid and risk factors for coronary artery disease. Am. J. Cardiol. 2001, 87:1411-1414.
16. De Luca G., Verdoia M., Cassetti E., et al. High fibrinogen level is an independent predictor of presence and extent of coronary artery disease among Italian population. J Thromb Thrombolysis 2011, 31:458-463.
17. De Luca G., van 't Hof A.W., de Boer M.J., et al. Time-to-treatment significantly affects the extent of ST-segment resolution and myocardial blush in patients with acute myocardial infarction treated by primary angioplasty. Eur. Heart J. 2004, 25:1009-1013.
18. De Luca G., Dirksen M.T., Spaulding C., Kelbæk H., Schalij M., Thuesen L., van der Hoeven B., Vink M.A., Kaiser C., Musto C., Chechi T., Spaziani G., Diaz de la Llera L.S., Pasceri V., Di Lorenzo E., Violini R., Suryapranata H., Stone G.W. DESERT cooperation. Impact of diabetes on long-term outcome after primary angioplasty: insights from the DESERT cooperation. Diabetes Care 2013, 36:1020-1025.
19. Boushey C.J., Beresfors S.A., et al. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease: probable benefits of increasing folic acid intakes. JAMA 1995, 274:1049-1057.
20. Zweier L., Kuppusamy P., Lutty G.A. Measurement of endothelial cell free radical generation: evidence for a central mechanism of free radical injury in postischemic tissues. Proc. Natl. Acad. Sci. U. S. A. 1988, 85:4046-4050.
21. Nieto F.J., Iribarren C., Gross M.D., et al. Uric acid and serum antioxidant capacity: a reaction to atherosclerosis?. Atherosclerosis 2000, 148:131-139.
22. Mazza A., Pessina A.C., Pavei A., et al. Predictors of stroke mortality in elderly people from the general population. The CArdiovascular STudy in the ELderly. Eur. J. Epidemiol. 2001, 17(12):1097-1104.
23. Ndrepepa G., Braun S., King L., et al. Association of uric acid with mortality in patients with stable coronary artery disease. Metabolism 2012, 61(12):1780-1786.
24. Culleton B.F., Larson M.G., Kannel W.B., Levy D. Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study. Ann. Intern Med. 1999, 131:7-13.
25. Panero F., Gruden G., Perotto M., et al. Uric acid is not an independent predictor of cardiovascular mortality in type 2 diabetes: a population-based study. Atherosclerosis 2012, 221:183-188.
26. Fang J., Alderman M.H. Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow up study, 1971-1992. National Health and Nutrition Examination Survey. JAMA 2000, 283:2404-2410.
27. Onat A., Can G., Örnek E., et al. Elevated serum uric acid in non diabetic people mark pro-inflammatory state and HDL dysfunction and independently predicts coronary disease. Clin. Rheumatol. 2013 Dec, 32(12):1767-1775.
28. Kim S.Y., Guevara J.P., Kim K.M., et al. Hyperuricemia and coronary heart disease: a systematic review and meta-analysis. Arthritis Care Res. 2010 Feb, 62(2):170-180.
29. Ndrepepa G., Cassese S., Braun S., et al. A gender-specific analysis of association between hyperuricaemia and cardiovascular events in patients with coronary artery disease. Nutr. Metab. Cardiovasc Dis. 2013 Dec, 23(12):1195-1201.
30. Neogi T. Asymptomatic hyperuricemia: perhaps not so benign?. J. Rheumatol. 2008, 35(5):734-737.
31. Fang J.I., Wu J.S., Yang Y.C., et al. High uric acid level associated with increased arterial stiffness in apparently healthy women. Atherosclerosis 2014 Oct, 236(2):389-393.
32. Tavil Y., Sen N., Yazici H.U., Hizal F., Abaci A., Cengel A., Tavil Y., Sen N., Yazici H.U., Hizal F., Abaci A., Cengel A. Mean platelet volume in patients with metabolic syndrome and its relationship with coronary artery disease. Thromb. Res. 2007, 120:245-250.
33. Tsiara S., Elisaf M., Jagroop I.A., Mikhailidis D.P. Platelets as predictors of vascular risk: is there a practical index of platelet activity?. Clin. Appl. Thromb. Hemost. 2003, 9:177-190.
34. Milionis H.J., Kakafika A.I., Tsouli S.G., et al. Effects of statin treatment on uric acid homeostasis in patients with primary hyperlipidemia. Am. Heart J. 2004, 148:635-640.
35. Strazzullo P., Puig J.G. Uric acid and oxidative stress: relative impact on cardiovascular risk?. Nutr. Metab. Cardiovasc Dis. 2007, 17:409-414.
36. Savarese G., Ferri C., Trimarco B., et al. Changes in serum uric acid levels and cardiovascular events: a meta-analysis. Nutr. Metab. Cardiovasc Dis. 2013, 23(8):707-714.
37. Hassani S.E., Mintz G.S., Fong H.S., et al. Negative remodeling and calcified plaque in octogenarians with acute myocardial infarction: an intravascular ultrasound analysis. J. Am. Coll. Cardiol. 2006, 47:2413-2419.